• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CVS Health (CVS) Journal Launch Keeps Its Undervalued Narrative In View

    Simply Wall St·11/14/2026 00:50:09
    Listen to the news

    CVS Health (CVS) stock is back in focus after a fresh consumer product update. CVS Pharmacy has rolled out new Caliber Artist Series journals that link everyday stationery with themes of health and community.

    For investors watching CVS Health, the latest Caliber journals arrive at a time when sentiment has been mixed. The share price is US$89.35, with a 7 day share price return of 6.56% but a 90 day share price return that has declined 8.04%. Meanwhile, the 1 year total shareholder return of 18.36% and 3 year total shareholder return of 45.40% point to a stronger longer term payoff pattern.

    Scan how CVS Health compares with a hand-picked 32 high quality undervalued stocks that pair everyday brands with stronger long term performance profiles and solid fundamentals.

    After a sharp 7 day bounce and a weaker 90 day stretch, CVS Health now sits at a level where investors are asking a simple question: Is the meaningful upside still ahead, or has most of it already played out?

    Most Popular Narrative: 28% Undervalued

    On the narrative view, CVS Health’s fair value of US$124 sits well above the last close at US$89.35, and the gap turns into a story about earnings power and structure risk rather than day to day sentiment. According to Andrei_Niculescu, a Simply Wall St Community investor who wrote the narrative, the key question is whether the current earnings base holds up as the group prepares for a planned split.

    Q3 2026 update (4 Nov): Aetna''s margin recovery is still the story, while the market focused on a different one. Revenue was US$108.4B (+5.4%), adjusted EPS US$2.09, and Health Care Benefits adjusted operating income nearly tripled to US$912M as the medical benefit ratio improved to 91.3% from 92.8%. Full-year 2026 adjusted EPS guidance is now at least US$8.20 (from US$7.90 to US$8.10), cash from operations at least US$15.5B (from ≥US$11.5B), and management put a 2027 adjusted EPS floor of at least US$8.65 while saying the mid-teens CAGR through 2028 is tracking the high end. Buybacks resume in Q4.

    See why 5 investors see CVS Health as 28% undervalued.

    Result: Fair Value of $124 (UNDERVALUED)

    Still, the CVS Health thesis could be knocked off course if medical cost trends spike again or pharmacy reimbursement pressure becomes harder than expected to manage.

    Find out about the key risks to this CVS Health narrative.

    Next Steps

    This mix of optimism and concern around CVS Health only matters if you actually test it for yourself and decide where you stand. To pressure test both sides of the story in one place, walk through the 5 key rewards and 1 important warning sign.

    Hunting For More Ideas Beyond CVS Health?

    If CVS Health has sharpened your interest, do not stop here. Broadening your watchlist can reveal opportunities that match your risk profile and income goals.